HUE057772T2 - Kristályos formák - Google Patents

Kristályos formák

Info

Publication number
HUE057772T2
HUE057772T2 HUE17771436A HUE17771436A HUE057772T2 HU E057772 T2 HUE057772 T2 HU E057772T2 HU E17771436 A HUE17771436 A HU E17771436A HU E17771436 A HUE17771436 A HU E17771436A HU E057772 T2 HUE057772 T2 HU E057772T2
Authority
HU
Hungary
Prior art keywords
crystalline forms
crystalline
forms
Prior art date
Application number
HUE17771436A
Other languages
English (en)
Hungarian (hu)
Inventor
Daniel Leuenberger
Stefan Reber
Raumer Markus Von
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of HUE057772T2 publication Critical patent/HUE057772T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUE17771436A 2016-09-22 2017-09-21 Kristályos formák HUE057772T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22

Publications (1)

Publication Number Publication Date
HUE057772T2 true HUE057772T2 (hu) 2022-06-28

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17771436A HUE057772T2 (hu) 2016-09-22 2017-09-21 Kristályos formák

Country Status (27)

Country Link
US (4) US10730896B2 (enExample)
EP (2) EP3981774A1 (enExample)
JP (1) JP7097369B2 (enExample)
KR (1) KR102552795B1 (enExample)
CN (1) CN109715639B (enExample)
AU (1) AU2017331930B2 (enExample)
CA (1) CA3037794A1 (enExample)
CL (1) CL2019000728A1 (enExample)
CY (1) CY1125052T1 (enExample)
DK (1) DK3515924T3 (enExample)
EA (1) EA201990723A1 (enExample)
ES (1) ES2908572T3 (enExample)
HR (1) HRP20220234T1 (enExample)
HU (1) HUE057772T2 (enExample)
IL (1) IL265445B2 (enExample)
LT (1) LT3515924T (enExample)
MA (1) MA46266B1 (enExample)
MX (1) MX381590B (enExample)
MY (1) MY193080A (enExample)
PH (1) PH12019500567B1 (enExample)
PL (1) PL3515924T3 (enExample)
PT (1) PT3515924T (enExample)
RS (1) RS62946B1 (enExample)
SI (1) SI3515924T1 (enExample)
TW (1) TWI752086B (enExample)
UA (1) UA124073C2 (enExample)
WO (1) WO2018055016A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3981774A1 (en) 2016-09-22 2022-04-13 Idorsia Pharmaceuticals Ltd Crystalline forms
EA201992123A1 (ru) 2017-03-15 2020-02-25 Идорсия Фармасьютиклз Лтд Подкожное введение антагониста p2yрецептора
EP4181872B1 (en) 2020-07-15 2025-11-26 Viatris Asia Pacific Pte. Ltd. Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist
US20240317784A1 (en) 2021-07-13 2024-09-26 Viatris Asia Pacific Pte. Ltd. Process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
EP1192132B1 (en) 1999-06-14 2005-09-07 Eli Lilly And Company Serine protease inhibitors
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
EP1578423B1 (en) 2002-12-11 2010-08-18 Bayer Schering Pharma Aktiengesellschaft 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
MXPA05010760A (es) 2003-04-09 2005-12-12 Wyeth Corp Derivados de acido 2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil fosfonico y su uso como antagonistas de receptor de n-metil-d-aspartato (nmda).
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
JP5164847B2 (ja) 2005-10-21 2013-03-21 アクテリオン ファーマシューティカルズ リミテッド 抗マラリア薬としての新規のピペラジン
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
MY153427A (en) 2007-04-23 2015-02-13 Sanofi Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
TWI361690B (en) 2007-11-29 2012-04-11 Actelion Pharmaceuticals Ltd Phosphonic acid derivatives
WO2009080226A2 (en) 2007-12-26 2009-07-02 Sanofis-Aventis Heterocyclic pyrazole-carboxamides as p2y12 antagonists
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AU2010233378A1 (en) 2009-04-08 2011-11-24 Actelion Pharmaceuticals Ltd. 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as ADP receptor antagonists
WO2010122504A1 (en) 2009-04-22 2010-10-28 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
EP3981774A1 (en) 2016-09-22 2022-04-13 Idorsia Pharmaceuticals Ltd Crystalline forms
EA201992123A1 (ru) 2017-03-15 2020-02-25 Идорсия Фармасьютиклз Лтд Подкожное введение антагониста p2yрецептора
EP4181872B1 (en) 2020-07-15 2025-11-26 Viatris Asia Pacific Pte. Ltd. Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist

Also Published As

Publication number Publication date
CN109715639A (zh) 2019-05-03
KR20190052704A (ko) 2019-05-16
IL265445A (en) 2019-05-30
PH12019500567A1 (en) 2019-11-18
LT3515924T (lt) 2022-03-10
HRP20220234T1 (hr) 2022-05-13
EP3981774A1 (en) 2022-04-13
JP2019529553A (ja) 2019-10-17
US12227532B2 (en) 2025-02-18
US20200017534A1 (en) 2020-01-16
KR102552795B1 (ko) 2023-07-06
MA46266B1 (fr) 2022-02-28
AU2017331930B2 (en) 2021-07-15
DK3515924T3 (da) 2022-03-21
MA46266A (fr) 2019-07-31
PL3515924T3 (pl) 2022-04-11
SI3515924T1 (sl) 2022-04-29
CY1125052T1 (el) 2024-02-16
WO2018055016A1 (en) 2018-03-29
RS62946B1 (sr) 2022-03-31
CN109715639B (zh) 2022-04-19
MX2019003093A (es) 2019-07-18
BR112019004845A2 (pt) 2019-06-04
US20220275011A1 (en) 2022-09-01
IL265445B2 (en) 2024-05-01
US11365209B2 (en) 2022-06-21
CL2019000728A1 (es) 2019-07-05
TW201813965A (zh) 2018-04-16
MY193080A (en) 2022-09-26
EP3515924B1 (en) 2021-12-15
US10730896B2 (en) 2020-08-04
EA201990723A1 (ru) 2019-10-31
EP3515924A1 (en) 2019-07-31
US20250163086A1 (en) 2025-05-22
PH12019500567B1 (en) 2024-01-31
NZ750772A (en) 2023-10-27
UA124073C2 (uk) 2021-07-14
AU2017331930A1 (en) 2019-03-07
US20210009614A1 (en) 2021-01-14
TWI752086B (zh) 2022-01-11
CA3037794A1 (en) 2018-03-29
MX381590B (es) 2025-03-12
IL265445B1 (en) 2024-01-01
JP7097369B2 (ja) 2022-07-07
ES2908572T3 (es) 2022-05-03
PT3515924T (pt) 2022-03-11

Similar Documents

Publication Publication Date Title
IL273730A (en) crystalline forms
AU201616677S (en) Cylindres
DK3438253T3 (en) Phytasemutant
DK3270751T3 (en) Foodprocessor
AU201710580S (en) Bookrack
SG10201911417PA (en) Crystalline compounds
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
IL262674A (en) crystals
GB201614939D0 (en) Crystalline hydrate
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
GB201419174D0 (en) Crystalline forms
HUE066360T2 (hu) Eravaciklin kristályformái
IL265445A (en) crystalline forms
IL253479A0 (en) Crystalline forms of efinconazole
PT3390358T (pt) Bis-cloridrato de eravaciclina cristalino
PL3350179T3 (pl) Krystaliczne postacie
DK3430092T3 (en) Coatingsystem
ZA201902553B (en) Crystalline forms
IL261795A (en) Crystalline form
GB201715010D0 (en) Crystalline forms
GB201708856D0 (en) Seletalisib crystalline forms
HK40009744A (en) Crystalline forms
GB201604759D0 (en) Crystalline compounds
GB201704789D0 (en) Crystalline compounds
AU5499P (en) T15-1218 Bituminaria bituminosa